Technology
Precision Deimmunization with Our ADAx Platform
The ADAx platform is an innovative technology that incorporates proprietary CD22 ligands (CD22L) on biologics to target and suppress therapeutic-specific B cells, while preserving the full functionality of the biologic.
Our Novel Approach
Tuned Affinity & Specificity
We’ve optimized natural CD22 ligands with enhanced binding affinity and specificity, enabling precise and targeted immune modulation.
Enhanced Pharmacological Activity
Our CD22L-conjugated biologics are designed to maintain full pharmacologic function while enhancing the therapeutic profile.
Safety and Durability
Our deimmunized biologics are designed to minimize immune responses and reduce adverse events while ensuring long-term therapeutic efficacy.
Our Mechanism - ADAx Pathway
Key features of our ADAx platform
- Selectively suppresses B cell receptor (BCR) activation specific to the therapeutic while preserving normal immune responses
- Cross-species reactivity of CD22 ligand enables preclinical evaluation of ADA suppression in vivo
- Demonstrated compatibility with various protein formats including antibodies, bispecifics, multi-domain proteins, and enzymes.
- Unlike other ADA mitigation techniques, ADAx avoids broad immune suppression, does not rely on epitope masking, and does not alter the tissue distribution of the drug.